Fibrinogen and fibrin clot structure in diabetes
- PMID: 15340732
- DOI: 10.1007/s00059-004-2607-z
Fibrinogen and fibrin clot structure in diabetes
Abstract
Diabetes is associated with an increased risk of developing cardiovascular disease, which is not fully accounted for by the accumulation of classic cardiovascular risk factors in patients. Recent evidence has demonstrated fibrinogen to be a powerful independent risk marker for cardiovascular disease in the general population, and it is also likely to contribute toward the increased atherosclerotic risk in diabetes. The etiology of hyperfibrinogenemia in diabetes is likely to be multifactorial, and at present the mechanisms involved have not been clarified. However, insulin, insulin resistance and inflammation are likely to be involved, especially in type 2 diabetes. The influence of diabetes in determining an individual's atherothrombotic risk is likely to extend beyond that of elevated fibrinogen levels, and may also act via changes in the structure and function of the fibrin clot that forms. Further research is needed to determine the mechanisms underlying these changes, which may lead to development of future interventions to reduce the excessive vascular risk associated with this disease.
Similar articles
-
The vulnerable blood. Coagulation and clot structure in diabetes mellitus.Hamostaseologie. 2015;35(1):25-33. doi: 10.5482/HAMO-14-09-0039. Epub 2014 Nov 24. Hamostaseologie. 2015. PMID: 25418205 Review.
-
Diabetes mellitus as a prothrombotic condition.J Intern Med. 2007 Aug;262(2):157-72. doi: 10.1111/j.1365-2796.2007.01824.x. J Intern Med. 2007. PMID: 17645584 Review.
-
Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects.Arterioscler Thromb Vasc Biol. 2006 Jun;26(6):1397-404. doi: 10.1161/01.ATV.0000219688.43572.75. Epub 2006 Mar 30. Arterioscler Thromb Vasc Biol. 2006. PMID: 16574890
-
Fibrinogen and fibrin: scaffold proteins in hemostasis.Curr Opin Hematol. 2007 May;14(3):236-41. doi: 10.1097/MOH.0b013e3280dce58c. Curr Opin Hematol. 2007. PMID: 17414213 Review.
-
The effect of glycaemic control on fibrin network structure of type 2 diabetic subjects.Thromb Haemost. 2006 Nov;96(5):623-9. Thromb Haemost. 2006. PMID: 17080220 Clinical Trial.
Cited by
-
Lipopolysaccharide-binding protein (LBP) can reverse the amyloid state of fibrin seen or induced in Parkinson's disease.PLoS One. 2018 Mar 1;13(3):e0192121. doi: 10.1371/journal.pone.0192121. eCollection 2018. PLoS One. 2018. PMID: 29494603 Free PMC article.
-
Fibrin Formation, Structure and Properties.Subcell Biochem. 2017;82:405-456. doi: 10.1007/978-3-319-49674-0_13. Subcell Biochem. 2017. PMID: 28101869 Free PMC article. Review.
-
Lipopolysaccharide-binding protein (LBP) reverses the amyloid state of fibrin seen in plasma of type 2 diabetics with cardiovascular co-morbidities.Sci Rep. 2017 Aug 29;7(1):9680. doi: 10.1038/s41598-017-09860-4. Sci Rep. 2017. PMID: 28851981 Free PMC article.
-
Diabetes and cardiovascular disease: pathophysiology of a life-threatening epidemic.Herz. 2016 May;41(3):184-92. doi: 10.1007/s00059-016-4414-8. Herz. 2016. PMID: 27026400 Review.
-
Fibrin accumulation secondary to loss of plasmin-mediated fibrinolysis drives inflammatory osteoporosis in mice.Arthritis Rheumatol. 2014 Aug;66(8):2222-33. doi: 10.1002/art.38639. Arthritis Rheumatol. 2014. PMID: 24664548 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical